Good
Mostly Aligned
Patient Risk:
Low
Summary
Most factual statements about Qinlock/ripretinib branding and the GIST indication after prior kinase inhibitors are supported by the provided label excerpts. One claim about indication depending on country labeling is not supported by the provided labeling information.
Category Scores
Accurate Statements
Qinlock is the brand name for ripretinib.
Label identifies QINLOCK as the drug; active ingredient provided is ripretinib.
Ripretinib (Qinlock) is a cancer medicine.
Indication section describes QINLOCK for treatment of advanced GIST (a cancer).
Ripretinib (Qinlock) is used for certain gastrointestinal stromal tumors (GIST) after other treatments.
INDICATIONS AND USAGE: adult advanced GIST patients who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Unsupported Statements
The specific indication for Qinlock depends on the specific indication and country labeling.
The provided label excerpts state a single FDA indication for QINLOCK and do not support that the indication depends on country labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Claims evaluated are largely descriptive of brand/drug identity and on-label use; the one unsupported statement relates to country-dependent indications rather than providing incorrect contraindication or dosing details.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication-dependence on country labeling is not supported by the provided FDA label excerpts.
Suggested Improvement
Replace the country-labeling conditional phrasing with the specific on-label indication text from the label excerpt (adult advanced GIST after prior treatment with 3 or more kinase inhibitors, including imatinib).